Akintunde Bello
Zitiert von
Zitiert von
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
RJ Motzer, TE Hutson, MR Olsen, GR Hudes, JM Burke, WJ Edenfield, ...
Journal of clinical oncology 30 (12), 1371-1377, 2012
Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug
M Morgen, C Bloom, R Beyerinck, A Bello, W Song, K Wilkinson, ...
Pharmaceutical research 29 (2), 427-440, 2012
Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma
CH Barrios, D Hernandez‐Barajas, MP Brown, SH Lee, L Fein, JH Liu, ...
Cancer 118 (5), 1252-1259, 2012
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang, J Shen, HE Vezina, ...
Annals of Oncology 28 (8), 2002-2008, 2017
Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects
DA Gajjar, A Bello, Z Ge, L Christopher, DM Grasela
Antimicrobial agents and chemotherapy 47 (7), 2256-2263, 2003
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections
S Van Wart, L Phillips, EA Ludwig, R Russo, DA Gajjar, A Bello, ...
Antimicrobial agents and chemotherapy 48 (12), 4766-4777, 2004
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
GV Long, SS Tykodi, JG Schneider, C Garbe, G Gravis, M Rashford, ...
Annals of Oncology 29 (11), 2208-2213, 2018
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
CJ Sweeney, EG Chiorean, CF Verschraegen, FC Lee, S Jones, M Royce, ...
Journal of clinical oncology 28 (29), 4513, 2010
Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.
C Li, C Alvey, A Bello, KD Wilner, W Tan
Journal of Clinical Oncology 29 (15_suppl), e13065-e13065, 2011
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
J Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M Gupta
The Journal of Clinical Pharmacology 57, S26-S42, 2017
Effects of the des-F (6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats
EM Kappel, M Shakibaei, A Bello, R Stahlmann
Antimicrobial agents and chemotherapy 46 (10), 3320-3322, 2002
Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer
Y Feng, X Wang, G Bajaj, S Agrawal, A Bello, B Lestini, FG Finckenstein, ...
Clinical Cancer Research 23 (18), 5394-5405, 2017
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
TR Johnson, W Tan, L Goulet, EB Smith, S Yamazaki, GS Walker, ...
Xenobiotica 45 (1), 45-59, 2015
Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects
J Andrews, D Honeybourne, G Jevons, M Boyce, R Wise, A Bello, ...
Journal of Antimicrobial Chemotherapy 51 (3), 727-730, 2003
Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma
L Gibiansky, C Passey, A Roy, A Bello, M Gupta
Journal of pharmacokinetics and pharmacodynamics 43 (3), 243-257, 2016
Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies
L Liu, A Bello, MJ Dresser, D Heald, SF Komjathy, E O'Mara, M Rogge, ...
The Journal of Clinical Pharmacology 56 (2), 143-151, 2016
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
MG Jannuzzo, E Di Salle, R Spinelli, N Pirotta, P Buchan, A Bello
Breast cancer research and treatment 113 (3), 491, 2009
Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
H Xu, M O'Gorman, T Boutros, N Brega, C Kantaridis, W Tan, A Bello
The Journal of Clinical Pharmacology 55 (1), 104-113, 2015
Effect of a High‐Fat Meal on the Pharmacokinetics of the Des‐F (6)‐Quinolone BMS‐284756
DA Gajjar, SC Sukoneck, A Bello, Z Ge, L Christopher, DM Grasela
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22 (2 …, 2002
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects
H Xu, M O’Gorman, W Tan, N Brega, A Bello
European journal of clinical pharmacology 71 (12), 1441-1449, 2015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20